FEMY News

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Form 8-K

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care